Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs UiPath Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.02B), while UiPath Inc trades at $11.98 (market cap $6.14B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is the larger of the two by market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, UiPath Inc nearer its low. Which is the better fit depends on your goals.
| BIO | PATH | |
|---|---|---|
Market Cap | $8.02B | $6.14B |
Sector | Health | Technology |
52-Week High | $339.75 | $19.29 |
52-Week Low | $241.71 | $9.38 |
Enterprise Value | $7.84B | $4.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
UiPath (PATH) trades at $11.85, up 1.46% with a bullish technical signal. The company shows improving fundamentals with revenue growing from $1.43B in 2025 to projected $1.7B in 2026, while transitioning from net losses to profitability. Recent earnings show mixed results with Q1 2026 missing expectations but strong gross margins of 83.01% highlight operational efficiency. Analyst consensus price target sits at $13.33 with 25% buy ratings.
PATH presents a compelling turnaround story with accelerating revenue growth and path to profitability. Key opportunities include agentic AI adoption through Maestro platform and expanding enterprise automation. Risks include execution challenges in AI monetization, competitive pressures, and the stock's premium valuation multiples requiring sustained growth delivery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
